Completed
Tecogalan Sodium Infusion for Kaposi's Sarcoma Treatment
What is being tested
Tecogalan sodium
Drug
Who is being recruted
Blood-Borne Infections+21
+ Urogenital Diseases
+ Genital Diseases
Over 18 Years
+16 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 1
Interventional
Summary
Principal SponsorDaiichi Pharmaceuticals
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Patients receive intravenous DS-4152 by infusion weekly for 4 weeks, followed by 2 weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.
Principal SponsorDaiichi Pharmaceuticals
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesDNA Virus InfectionsHerpesviridae InfectionsImmunologic Deficiency SyndromesImmune System DiseasesInfectionsNeoplasms by Histologic TypeNeoplasms, Vascular TissueRetroviridae InfectionsRNA Virus InfectionsSarcomaSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsNeoplasms, Connective and Soft TissueAcquired Immunodeficiency SyndromeNeoplasmsSarcoma, KaposiHIV Infections
Criteria
4 inclusion criteria required to participate
Life expectancy of at least 12 weeks.
Recovered from toxicity of any prior anticancer therapy.
NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks.
Kaposi's sarcoma plus HIV infection OR metastatic solid tumor.
12 exclusion criteria prevent from participating
Other investigational agents.
Extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors.
Symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy.
Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C).
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Kenneth Norris Jr Cancer Ctr / USC
Los Angeles, United StatesOpen Kenneth Norris Jr Cancer Ctr / USC in Google MapsCompletedOne Study Center